Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inamed wrinkle treatments

This article was originally published in The Gray Sheet

Executive Summary

Firm receives supplemental PMA approval for CosmoDerm and CosmoPlast human collagen devices March 12. CosmoDerm is indicated for use in "the superficial papillary dermis for correction of soft tissue contour deficiencies such as wrinkles and acne scars," while CosmoPlast "is injected into the mid to deep dermis for the same results." The approvals are based on an earlier PMA for Zyderm and Zyplast bovine collagen products. The devices, which use Advanced Tissue Sciences' human collagen, require no skin-allergy testing prior to injection. Artes Medical's PMMA/collagen implant may not be far behind following an FDA panel nod last month (1"The Gray Sheet" March 3, 2003, p. 26)...

You may also be interested in...



Artefill PMMA/Collagen Implant Gains Panel Nod With Conditions

Artes Medical should develop patient and physician educational materials for its Artefill PMMA/collagen dermal implant in addition to standard labeling, FDA's General & Plastic Surgery Devices Panel recommends

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018040

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel